All In Biotech

Drug Trial Radar · NCT02465567

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)

Last checked: Nov 19, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,588 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,588

Actual

Start

Jun 30, 2015

Primary completion

Jul 26, 2019

Study completion Jul 26, 2019

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.

Conditions

  • COPD

Interventions

  • BGF MDI 320/14.4/9.6 μgDrug

    Budensonide, Glycopyrronium, and Formoterol Fumarate

  • GFF MDI 14.4/9.6 μgDrug

    Glycopyrronium, and Formoterol Fumarate

  • BGF MDI 160/14.4/9.6 μgDrug

    Budensonide, Glycopyrronium, and Formoterol Fumarate

  • BFF MDI 320/9.6 μgDrug

    Budensonide, and Formoterol Fumarate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Rate of Moderate or Severe ExacerbationsTime frame: 52-week treatment period

Locations

741 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Andalusia, Alabama

  • Research Site

    Athens, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Dothan, Alabama

  • Research Site

    Florence, Alabama

  • Research Site

    Foley, Alabama

  • Research Site

    Gulf Shores, Alabama

  • Research Site

    Jasper, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Montgomery, Alabama

  • Research Site

    Scottsboro, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Peoria, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Conway, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    North Little Rock, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Cerritos, California

  • Research Site

    El Cajon, California

  • Research Site

    Escondido, California

  • Research Site

    Fresno, California

  • Research Site

    Gold River, California

  • Research Site

    Hawaiian Gardens, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Huntington Park, California

  • Research Site

    La Mirada, California

  • Research Site

    Lakewood, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

Showing 40 of 741 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.